Clinical trial for Type 2 Diabetes Mellitus
Official title Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes
ClinicalTrials.gov ID: NCT07868666
What this study is testing
- What it's testing
- This study will evaluate the feasibility of using a clinical decision support(CDS) message to support consideration of SGLT2 inhibitor prescribing in patients with type 2 diabetes who recently had acute kidney injury.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 75
You may be able to join if
- Assigned to work in a primary care specialty as a medical provider or assigned to work as a clinic pharmacist
- Scheduled to be seen in a participating clinic with a physician or advanced practice provider in a primary care specialty or a clinic pharmacist
- Medical history of acute kidney injury during a hospitalization with discharge within 1 year before the scheduled appointment
- Medical history of type 2 diabetes mellitus (by billing code)
- Age 30 to 75 years at the date of study enrollment
You likely can't join if
- Opted out of research use of AHC/M Health Fairview data shelter data
- History of kidney transplantation as a recipient(by billing code)
- Pregnancy documented in AHC/M Health Fairview data shelter data (by billing code)
- SGLT2i allergy in the EHR allergy list
- Medical history of diabetic ketoacidosis, dementia, hospice care, or oncology care (by billing code and/or encounter)
- Medical history in the prior 1 year of indwelling Foley urinary catheter, cystitis, pyelonephritis, prostatitis, or urinary tract infection (by...
See the full eligibility criteria
- Assigned to work in a primary care specialty as a medical provider or assigned to work as a clinic pharmacist
- Scheduled to be seen in a participating clinic with a physician or advanced practice provider in a primary care specialty or a clinic pharmacist
- Medical history of acute kidney injury during a hospitalization with discharge within 1 year before the scheduled appointment
- Medical history of type 2 diabetes mellitus (by billing code)
- Age 30 to 75 years at the date of study enrollment
- Available eGFR from labs more than 3 business days before the scheduled appointment and after AKI onset that is at least 30 mL/min/1.73 m²
- Either a serum creatinine lab measured after discharge from the hospitalization including the AKI, or the last serum creatinine lab during the hospitalization with AKI is less than 0.3 mg/dL above the patient's baseline...
- Opted out of research use of AHC/M Health Fairview data shelter data
- History of kidney transplantation as a recipient(by billing code)
- Pregnancy documented in AHC/M Health Fairview data shelter data (by billing code)
- SGLT2i allergy in the EHR allergy list
- Medical history of diabetic ketoacidosis, dementia, hospice care, or oncology care (by billing code and/or encounter)
- Medical history in the prior 1 year of indwelling Foley urinary catheter, cystitis, pyelonephritis, prostatitis, or urinary tract infection (by billing code)
- Serum creatinine rise of at least 0.3 mg/dL between the two most recent serum creatinine measurements
- Children
- Prisoners
The study team makes the final eligibility decision.
Where it is enrolling
- Minneapolis, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Minneapolis, Minnesota, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.